Laura Cancedda, PhD, principal investigator at the Italian Institute of Technology

Advanced Preclinical Testing of NKCC1 Inhibitors Supporting Phase 2 Trials in Fragile X

The project evaluates a next-generation NKCC1 inhibitor, studying its safety and effects on brain signaling to determine its potential to progress into Phase 2 clinical trials.

Read More »

Categories

FRAXA Funded Research

Current Research Grants (43)